miR‐320a regulates high mobility group box 1 expression and inhibits invasion and metastasis in hepatocellular carcinoma

Lv, Guixiang; Wu, Mingjuan; Wang, Meijie; Jiang, Xiaochen; Du, Jingli; Zhang, Kaili; Li, Dongliang; Ma, Ning; Peng, Yahui; Wang, Lujing; Zhou, Lingyun; Zhao, Weihua; Jiao, Yu‐Fei; Gao, Xu; Hu, Zheng

doi:10.1111/liv.13424

Cited by 33 publications

(30 citation statements)

References 33 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The up-regulation of SUMO1P3 resulted in the down-regulation of miR-320a, which could promote HCC cell proliferation and invasion, thus contributing to malignant growth and metastasis. [23][24][25] Our results were in line with those from published articles. The interaction between SUMO1P3 and miR-320a was also confirmed in breast cancer.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Long non‐coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β‐catenin signalling pathway by targeting miR‐320a

Chen

Lin

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

In this study, we aimed to investigate expression profile of long non‐coding RNA (lncRNA) SUMO1P3, and its role and molecular mechanisms in the progression of hepatocellular carcinoma (HCC). The expression of SUMO1P3 in HCC tissues and cells was detected using quantitative real‐time polymerase chain reaction (qRT‐PCR). The chi‐squared test was used to estimate the relationship between SUMO1P3 levels and clinical characteristics of HCC cases. Cellular biological behaviours were investigated using MTT, transwell assays and wound healing assay. Bioinformatics and dual‐luciferase reporter assays were performed to identify potential target of SUMO1P3 in HCC. Additionally, protein analysis was carried out using Western blot. The expression of SUMO1P3 was significantly higher in HCC tissues and cells than in non‐cancerous specimens and normal cells (P < .01). Moreover, its up‐regulation was closely correlated with lymph node metastasis (P = .027) and TNM stage (P = .019). SUMO1P3 knockdown inhibited the proliferation, migration and invasion of HCC cells. MiR‐320a was a potential target of SUMO1P3, and its expression was negatively regulated by SUMO1P3 in HCC SUMO1P3 could activate Wnt/β‐catenin pathway, which was mediated by miR‐320a. Elevated expression of SUMO1P3 predicts malignant progression among HCC patients. SUMO1P3 enhances Wnt/β‐catenin pathway through sponging miR‐320a, thus contributing to aggressive progression of HCC.

show abstract

Section: Discussionsupporting

confidence: 92%

“…SUMO1P3 could negatively regulate the expression of miR‐320a in HCC. The up‐regulation of SUMO1P3 resulted in the down‐regulation of miR‐320a , which could promote HCC cell proliferation and invasion, thus contributing to malignant growth and metastasis . Our results were in line with those from published articles.…”

Section: Discussionsupporting

confidence: 90%

Long non‐coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β‐catenin signalling pathway by targeting miR‐320a

Chen

Lin

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…(12)(13)(14) In this latter role, HMGB1 acts as a proinflammatory cytokine that contributes to multiple injuries, including those from the liver, such as warm and cold ischemia/reperfusion (I/R) injury, (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27) sepsis, (23,(28)(29)(30)(31)(32) acetaminophen (APAP) intoxication, (23,(33)(34)(35)(36)(37)(38)(39)(40) alcoholic liver disease (ALD), (41)(42)(43) fibrosis, (44)(45)(46)(47)(48)(49) nonalcoholic steatohepatitis (NASH), (50)(51)(52) and hepatocellular carcinoma (HCC). (53)(54)(55)(56)(57)…”

mentioning

confidence: 99%

High‐Mobility Group Box‐1 and Liver Disease

Gaskell

Nieto

2018

Hepatology Communications

View full text Add to dashboard Cite

High‐mobility group box‐1 (HMGB1) is a ubiquitous protein. While initially thought to be simply an architectural protein due to its DNA‐binding ability, evidence from the last decade suggests that HMGB1 is a key protein participating in the pathogenesis of acute liver injury and chronic liver disease. When it is passively released or actively secreted after injury, HMGB1 acts as a damage‐associated molecular pattern that communicates injury and inflammation to neighboring cells by the receptor for advanced glycation end products or toll‐like receptor 4, among others. In the setting of acute liver injury, HMGB1 participates in ischemia/reperfusion, sepsis, and drug‐induced liver injury. In the context of chronic liver disease, it has been implicated in alcoholic liver disease, liver fibrosis, nonalcoholic steatohepatitis, and hepatocellular carcinoma. Recently, specific posttranslational modifications have been identified that could condition the effects of the protein in the liver. Here, we provide a detailed review of how HMGB1 signaling participates in acute liver injury and chronic liver disease.

show abstract

“…Strikingly, in addition to proteins regulating gene expression, we also identified tight junction proteins TJP1 and TJP2 among HMGB1 interacting proteins. This is remarkable in light of HMGB1’s role in metastasis [ 14 , 28 ] and points to potential players cooperating with HMGB1 to promote metastasis.…”

Section: Resultsmentioning

confidence: 99%

Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer

et al. 2018

View full text Add to dashboard Cite

High Mobility Group B (HMGB) proteins are involved in cancer progression and in cellular responses to platinum compounds used in the chemotherapy of prostate and ovary cancer. Here we use affinity purification coupled to mass spectrometry (MS) and yeast two-hybrid (Y2H) screening to carry out an exhaustive study of HMGB1 and HMGB2 protein interactions in the context of prostate and ovary epithelia. We present a proteomic study of HMGB1 partners based on immunoprecipitation of HMGB1 from a non-cancerous prostate epithelial cell line. In addition, HMGB1 and HMGB2 were used as baits in yeast two-hybrid screening of libraries from prostate and ovary epithelial cell lines as well as from healthy ovary tissue. HMGB1 interacts with many nuclear proteins that control gene expression, but also with proteins that form part of the cytoskeleton, cell-adhesion structures and others involved in intracellular protein translocation, cellular migration, secretion, apoptosis and cell survival. HMGB2 interacts with proteins involved in apoptosis, cell motility and cellular proliferation. High confidence interactors, based on repeated identification in different cell types or in both MS and Y2H approaches, are discussed in relation to cancer. This study represents a useful resource for detailed investigation of the role of HMGB1 in cancer of epithelial origins, as well as potential alternative avenues of therapeutic intervention.

show abstract

miR‐320a regulates high mobility group box 1 expression and inhibits invasion and metastasis in hepatocellular carcinoma

Abstract: Our results showed that miR-320a was involved in the invasion and metastasis by targeting HMGB1 and had an anti-metastasis effect in HCC.

Cited by 33 publications

References 33 publications

Long non‐coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β‐catenin signalling pathway by targeting miR‐320a

Long non‐coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β‐catenin signalling pathway by targeting miR‐320a

High‐Mobility Group Box‐1 and Liver Disease

Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer

Contact Info

Product

Resources

About